A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study

J. Van Eys, D. Berry, W. Crist, E. Doering, D. Fernbach, J. Pullen, J. Shuster, M. Wharam

Research output: Contribution to journalArticle

Abstract

Four hundred thirty patients with high-risk acute lymphoid leukemia were entered on the acute leukemia in childhood protocol (AlinC 12) of the Pediatric Division of the Southwest Oncology Group (now the Pediatric Oncology Group) between 1976 and 1979. This study was a prospective randomized comparison of two regimens that had as their primary differences: (1) an intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; (2) a period of intravenous methotrexate before initiating maintenance; and (3) in the regimen that had those two additions, triple-drug chemoprophylaxis of the central nervous system (CNS) using methotrexate, hydrocortisone, and cytosine arabinoside as compared to cranial irradiation and intrathecal methotrexate. All patients received vincristine and prednisone induction, 6-mercaptopurine and methotrexate maintenance, and vincristine and prednisone pulse intensification. There was no significant difference in the rate of bone marrow relapse. However, overall disease-free survival favored the arm with intensification and chemoprophylaxis because of a lesser incidence of extramedullary relapse. Thus, for treatment 1 versus treatment 3 the two-sided P values were for overall disease-free survival 0.16; bone marrow relapses 0.13; all CNS relapses 0.04; and all extramedullary disease relapses 0.013. It is concluded that intensification as delivered in this protocol protects against testicular relapse and that chemoprophylaxis is adequate prophylaxis against isolated CNS relapse.

Original languageEnglish (US)
Pages (from-to)23-29
Number of pages7
JournalCancer
Volume63
Issue number1
StatePublished - 1989

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatrics
Recurrence
Methotrexate
Chemoprevention
Vincristine
Prednisone
Cyclophosphamide
Disease-Free Survival
Central Nervous System
Bone Marrow
Maintenance
Central Nervous System Agents
Cranial Irradiation
Asparaginase
6-Mercaptopurine
Cytarabine
Hydrocortisone
Leukemia
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Eys, J., Berry, D., Crist, W., Doering, E., Fernbach, D., Pullen, J., ... Wharam, M. (1989). A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study. Cancer, 63(1), 23-29.

A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study. / Van Eys, J.; Berry, D.; Crist, W.; Doering, E.; Fernbach, D.; Pullen, J.; Shuster, J.; Wharam, M.

In: Cancer, Vol. 63, No. 1, 1989, p. 23-29.

Research output: Contribution to journalArticle

Van Eys, J, Berry, D, Crist, W, Doering, E, Fernbach, D, Pullen, J, Shuster, J & Wharam, M 1989, 'A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study', Cancer, vol. 63, no. 1, pp. 23-29.
Van Eys J, Berry D, Crist W, Doering E, Fernbach D, Pullen J et al. A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study. Cancer. 1989;63(1):23-29.
Van Eys, J. ; Berry, D. ; Crist, W. ; Doering, E. ; Fernbach, D. ; Pullen, J. ; Shuster, J. ; Wharam, M. / A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study. In: Cancer. 1989 ; Vol. 63, No. 1. pp. 23-29.
@article{90159a86e00a4011b25fbb87335a720e,
title = "A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study",
abstract = "Four hundred thirty patients with high-risk acute lymphoid leukemia were entered on the acute leukemia in childhood protocol (AlinC 12) of the Pediatric Division of the Southwest Oncology Group (now the Pediatric Oncology Group) between 1976 and 1979. This study was a prospective randomized comparison of two regimens that had as their primary differences: (1) an intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; (2) a period of intravenous methotrexate before initiating maintenance; and (3) in the regimen that had those two additions, triple-drug chemoprophylaxis of the central nervous system (CNS) using methotrexate, hydrocortisone, and cytosine arabinoside as compared to cranial irradiation and intrathecal methotrexate. All patients received vincristine and prednisone induction, 6-mercaptopurine and methotrexate maintenance, and vincristine and prednisone pulse intensification. There was no significant difference in the rate of bone marrow relapse. However, overall disease-free survival favored the arm with intensification and chemoprophylaxis because of a lesser incidence of extramedullary relapse. Thus, for treatment 1 versus treatment 3 the two-sided P values were for overall disease-free survival 0.16; bone marrow relapses 0.13; all CNS relapses 0.04; and all extramedullary disease relapses 0.013. It is concluded that intensification as delivered in this protocol protects against testicular relapse and that chemoprophylaxis is adequate prophylaxis against isolated CNS relapse.",
author = "{Van Eys}, J. and D. Berry and W. Crist and E. Doering and D. Fernbach and J. Pullen and J. Shuster and M. Wharam",
year = "1989",
language = "English (US)",
volume = "63",
pages = "23--29",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study

AU - Van Eys, J.

AU - Berry, D.

AU - Crist, W.

AU - Doering, E.

AU - Fernbach, D.

AU - Pullen, J.

AU - Shuster, J.

AU - Wharam, M.

PY - 1989

Y1 - 1989

N2 - Four hundred thirty patients with high-risk acute lymphoid leukemia were entered on the acute leukemia in childhood protocol (AlinC 12) of the Pediatric Division of the Southwest Oncology Group (now the Pediatric Oncology Group) between 1976 and 1979. This study was a prospective randomized comparison of two regimens that had as their primary differences: (1) an intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; (2) a period of intravenous methotrexate before initiating maintenance; and (3) in the regimen that had those two additions, triple-drug chemoprophylaxis of the central nervous system (CNS) using methotrexate, hydrocortisone, and cytosine arabinoside as compared to cranial irradiation and intrathecal methotrexate. All patients received vincristine and prednisone induction, 6-mercaptopurine and methotrexate maintenance, and vincristine and prednisone pulse intensification. There was no significant difference in the rate of bone marrow relapse. However, overall disease-free survival favored the arm with intensification and chemoprophylaxis because of a lesser incidence of extramedullary relapse. Thus, for treatment 1 versus treatment 3 the two-sided P values were for overall disease-free survival 0.16; bone marrow relapses 0.13; all CNS relapses 0.04; and all extramedullary disease relapses 0.013. It is concluded that intensification as delivered in this protocol protects against testicular relapse and that chemoprophylaxis is adequate prophylaxis against isolated CNS relapse.

AB - Four hundred thirty patients with high-risk acute lymphoid leukemia were entered on the acute leukemia in childhood protocol (AlinC 12) of the Pediatric Division of the Southwest Oncology Group (now the Pediatric Oncology Group) between 1976 and 1979. This study was a prospective randomized comparison of two regimens that had as their primary differences: (1) an intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; (2) a period of intravenous methotrexate before initiating maintenance; and (3) in the regimen that had those two additions, triple-drug chemoprophylaxis of the central nervous system (CNS) using methotrexate, hydrocortisone, and cytosine arabinoside as compared to cranial irradiation and intrathecal methotrexate. All patients received vincristine and prednisone induction, 6-mercaptopurine and methotrexate maintenance, and vincristine and prednisone pulse intensification. There was no significant difference in the rate of bone marrow relapse. However, overall disease-free survival favored the arm with intensification and chemoprophylaxis because of a lesser incidence of extramedullary relapse. Thus, for treatment 1 versus treatment 3 the two-sided P values were for overall disease-free survival 0.16; bone marrow relapses 0.13; all CNS relapses 0.04; and all extramedullary disease relapses 0.013. It is concluded that intensification as delivered in this protocol protects against testicular relapse and that chemoprophylaxis is adequate prophylaxis against isolated CNS relapse.

UR - http://www.scopus.com/inward/record.url?scp=0024536975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024536975&partnerID=8YFLogxK

M3 - Article

C2 - 2910421

AN - SCOPUS:0024536975

VL - 63

SP - 23

EP - 29

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -